全文获取类型
收费全文 | 1278709篇 |
免费 | 92843篇 |
国内免费 | 1987篇 |
专业分类
耳鼻咽喉 | 18199篇 |
儿科学 | 42314篇 |
妇产科学 | 37868篇 |
基础医学 | 187169篇 |
口腔科学 | 35453篇 |
临床医学 | 108484篇 |
内科学 | 252047篇 |
皮肤病学 | 26591篇 |
神经病学 | 99237篇 |
特种医学 | 49994篇 |
外国民族医学 | 366篇 |
外科学 | 197852篇 |
综合类 | 26591篇 |
现状与发展 | 1篇 |
一般理论 | 316篇 |
预防医学 | 92687篇 |
眼科学 | 29100篇 |
药学 | 97955篇 |
1篇 | |
中国医学 | 2497篇 |
肿瘤学 | 68817篇 |
出版年
2018年 | 11809篇 |
2015年 | 11645篇 |
2014年 | 16031篇 |
2013年 | 24391篇 |
2012年 | 33556篇 |
2011年 | 35944篇 |
2010年 | 21275篇 |
2009年 | 20084篇 |
2008年 | 34986篇 |
2007年 | 37961篇 |
2006年 | 38517篇 |
2005年 | 37800篇 |
2004年 | 36387篇 |
2003年 | 35391篇 |
2002年 | 34925篇 |
2001年 | 58122篇 |
2000年 | 59597篇 |
1999年 | 50730篇 |
1998年 | 14303篇 |
1997年 | 12887篇 |
1996年 | 13174篇 |
1995年 | 12425篇 |
1994年 | 11819篇 |
1993年 | 10915篇 |
1992年 | 41039篇 |
1991年 | 40409篇 |
1990年 | 39923篇 |
1989年 | 38743篇 |
1988年 | 36164篇 |
1987年 | 35399篇 |
1986年 | 33779篇 |
1985年 | 32170篇 |
1984年 | 23967篇 |
1983年 | 20853篇 |
1982年 | 12405篇 |
1981年 | 10955篇 |
1980年 | 10232篇 |
1979年 | 22661篇 |
1978年 | 15906篇 |
1977年 | 13747篇 |
1976年 | 12991篇 |
1975年 | 14222篇 |
1974年 | 16697篇 |
1973年 | 16082篇 |
1972年 | 15325篇 |
1971年 | 14241篇 |
1970年 | 13222篇 |
1969年 | 12744篇 |
1968年 | 11989篇 |
1967年 | 10485篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
David G Hicks Brian J Yoder Sarah Short Shannon Tarr Nichole Prescott Joseph P Crowe Andrea E Dawson G Thomas Budd Steven Sizemore Muzaffer Cicek Toni K Choueiri Raymond R Tubbs Daniel Gaile Norma Nowak Mary Ann Accavitti-Loper Andra R Frost Danny R Welch Graham Casey 《Clinical cancer research》2006,12(22):6702-6708
PURPOSE: This study aims to determine the effect of loss of breast cancer metastasis suppressor 1 (BRMS1) protein expression on disease-free survival in breast cancer patients stratified by estrogen receptor (ER), progesterone receptor (PR), or HER2 status, and to determine whether loss of BRMS1 protein expression correlated with genomic copy number changes. EXPERIMENTAL DESIGN: A tissue microarray immunohistochemical analysis was done on tumors of 238 newly diagnosed breast cancer patients who underwent surgery at the Cleveland Clinic between January 1, 1995 and December 31, 1996, and a comparison was made with 5-year clinical follow-up data. Genomic copy number changes were determined by array-based comparative genomic hybridization in 47 breast cancer cases from this population and compared with BRMS1 staining. RESULTS: BRMS1 protein expression was lost in nearly 25% of cases. Patients with tumors that were PR negative (P=0.006) or HER2 positive (P=0.039) and <50 years old at diagnosis (P=0.02) were more likely to be BRMS1 negative. No overall correlation between BRMS1 staining and disease-free survival was observed. A significant correlation, however, was seen between loss of BRMS1 protein expression and reduced disease-free survival when stratified by either loss of ER (P=0.008) or PR (P=0.029) or HER2 overexpression (P=0.026). Overall, there was poor correlation between BRMS1 protein staining and copy number status. CONCLUSIONS: These data suggest a mechanistic relationship between BRMS1 expression, hormone receptor status, and HER2 growth factor. BRMS1 staining could potentially be used in patient stratification in conjunction with other prognostic markers. Further, mechanisms other than genomic deletion account for loss of BRMS1 gene expression in breast tumors. 相似文献
993.
994.
M. E. Falagas S. K. Kasiakou D. P. Kofteridis G. Roditakis G. Samonis 《European journal of clinical microbiology & infectious diseases》2006,25(9):596-599
The prospective case series study presented here was conducted to assess the outcome of patients with infections caused by polymyxin-only-susceptible (POS) gram-negative bacteria managed with intravenous colistin. Between July 2003 and April 2005 a total of 27 patients were infected with a POS gram-negative bacterium and received intravenous colistin at a dose of 2 million international units (MIU) (160 mg or 66.7 mg colistin base) every 8 h for a mean (±SD) duration of 13.9 (±7.5) days. Nine patients had ventilator-associated pneumonia and received, in addition to the intravenous colistin therapy, 1 MIU (80 mg or 33.3 mg colistin base) aerosolized colistin every 12 h for a mean (±SD) duration of 13 (±6.5) days. The predominant pathogens were Pseudomonas aeruginosa (n=17) and Acinetobacter baumannii (n=12); in two patients both pathogens were isolated from one clinical specimen. In-hospital mortality and clinical response were 15% and 85%, respectively. Colistin-associated nephrotoxicity was observed in two of the 27 patients. POS gram-negative pathogens represent a major threat for hospitalized patients. Colistin appears to be an effective and safe treatment, even in patients with severe underlying diseases. 相似文献
995.
Timson C Appanna Shareen H Doak Spencer A Jenkins Howard G Kynaston Timothy P Stephenson James M Parry 《International journal of urology》2007,14(6):539-544
OBJECTIVE: Tumors arising within augmentation cystoplasties are aggressive, have poor prognosis and the majority are not detected at follow-up cystoscopy. Genetic changes in tumors precede morphological abnormalities. Therefore, the aim of this study was to investigate whether genetic abnormalities detected by comparative genomic hybridization (CGH) could be used to identify those patients with augmentation cystoplasties at increased risk of tumorigenesis. METHODS: Bladder biopsy samples were obtained from 16 augmentation cystoplasty patients both distant from and near to the enterovesical anastomosis. CGH was used to detect genetic abnormalities in DNA extracted from the biopsies, archival specimens of two augmentation cystoplasties and two de novo bladder adenocarcinomas. RESULTS: A greater number of amplifications on 2p, 3q, 8q, 9p, 17p, 18pq and 20pq, were observed in bladder biopsies obtained near to the enterovesical anastomosis compared to those taken distant to the suture line. CGH of archival augmentation cystoplasty tumor DNA indicated abnormalities at several loci with amplifications at 2q, 5q, 10p and 21pq, while deletions occurred at 5p and 16p. CONCLUSIONS: The results of this study suggest that the urothelium adjacent to the bladder and/or bowel anastomosis in augmentation cystoplasties is genetically unstable. Furthermore, longitudinal studies are required to establish whether or not patients exhibiting genetic instability following augmentation cystoplasty are at greater risk of developing tumors than those with genetically stable epithelia. 相似文献
996.
G Fitze J Cramer A Serra M Schreiber D Roesner H K Schackert 《Zeitschrift für Kinderchirurgie》2003,13(3):152-157
Hirschsprung disease (HSCR) is considered a model for a complex inheritance disorder. Several genes, including the major HSCR-susceptibility RET proto-oncogene, play an aetiological role in the development of HSCR. Genetic linkage analysis in familial HSCR with both long- and short-segment phenotypes has demonstrated a tight linkage to the RET locus, while the phenotype within a HSCR family is characterised by an incomplete penetrance or a variable extension of the aganglionosis. Therefore, additional genetic alterations of RET are postulated in the aetiology or modification of the HSCR phenotype. In this study, the coding region of all 21 exons of the RET proto-oncogene, including the flanking intronic sequences, were investigated by direct DNA sequencing in a HSCR population. We genotyped the c.135 G/A polymorphism and resolved haplotypes comprising the mutation locus and the c.135 G/A polymorphism. Twenty different mutations were detected in 18 of 76 HSCR patients. In ten families the mutations were inherited from the parents, while only four patients had a positive family history for the disease. Moreover, in all ten families an incomplete penetrance of the HSCR phenotype was observed. We have investigated the effect of the non-mutated wild-type allele as well as the c.135 G/A polymorphism on the phenotype within the HSCR families. Our findings support the notion that both RET alleles are involved in the pathogenesis of a subgroup of HSCR patients in a dose-dependent fashion. Additionally, we have shown a modifying effect of the c.135 G/A polymorphism on the HSCR phenotype within HSCR families. 相似文献
997.
998.
999.
1000.